About BioNTech R&D Austria
BioNTech R&D Austria is a wholly owned subsidiary of BioNTech SE, focused on the development of novel antibacterial drugs to treat persistent bacterial infections. Our development programs are based on our proprietary LysinBuilder platform, which allows the targeted development of synthetic lysins for virtually any bacterial pathogen. We use a combination of in-silico prediction, synthetic assembly and directed evolution to generate artificial lysins and develop them into drugs. The development pipeline focuses on chronic bacterial infections where antibiotics fail to cure or destroy the natural microbiomes. Our lead asset is PM-477, which we develop for the treatment of bacterial vaginosis. We also work on transforming the standard of care with lysins against several other infections and dysbiosis.
About the speakers
In the event the Co-Founder of PhagoMed and now Managing Director of BioNTech R&D (Austria) Dr. Lorenzo Corsini together with team member Ann-Katrin Kieniger, a recent PhD graduate will talk about the scientific platform and expansion plans in Vienna, what it’s like to join a biotech and career opportunities at BioNTech R&D (Austria).
Catering
After the talk there will be opportunity to ask questions and explore career options over some drinks. Please note the 2G rule applies.
Do not miss the chance
This is a fantastic opportunity to explore research positions in industry! If you are not sure whether start-up or large scale corporate biotech is the right thing for you, perhaps this a good event to find out. BioNTech R&D (Austria) will offer a number of career opportunities in the near future. Make sure to have a head-start if you will be on the job market soon. If you still have time, get informed about what working in industry could be like.